Analysts Offer Insights on Healthcare Companies: Crescent Biopharma (CBIO) and Viridian Therapeutics (VRDN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Crescent Biopharma (CBIO – Research Report) and Viridian Therapeutics (VRDN – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Crescent Biopharma (CBIO)
LifeSci Capital analyst Charles Zhu maintained a Buy rating on Crescent Biopharma today and set a price target of $22.00. The company’s shares closed last Thursday at $12.35.
According to TipRanks.com, Zhu is a 5-star analyst with an average return of
Currently, the analyst consensus on Crescent Biopharma is a Strong Buy with an average price target of $30.14, representing a 145.2% upside. In a report issued on February 19, Piper Sandler also maintained a Buy rating on the stock with a $35.00 price target.
See the top stocks recommended by analysts >>
Viridian Therapeutics (VRDN)
LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Viridian Therapeutics today and set a price target of $46.00. The company’s shares closed last Thursday at $29.49.
According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viridian Therapeutics with a $41.88 average price target, which is a 54.8% upside from current levels. In a report issued on February 17, Needham also maintained a Buy rating on the stock with a $42.00 price target.
